ALTIMMUNE, INC.

ALT · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).

Market Data

Price $3.11 +0.16 (+5.42%)

Market Cap$559M

P/E Ratio—

EPS$—

52W High$6.44

52W Low$2.56

Beta0.01

Data from Finnhub · Updated Aug 24, 2026